Leukemia - Table of Contents alert Volume 27 Issue 11

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 27, Issue 11 (November 2013) In this issue Original Articles Letters to the Editor Erratum Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Choose Scientific Reports for fast, efficient, open access publishing  94% of authors said they are likely or very likely to recommend Scientific Reports to their colleagues* 91% of authors would publish in Scientific Reports again*  SUBMIT your paper today!  *Nature Publishing Group author survey, data correct as of September 2013 Original Articles Top THERAPY Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning F Malard, S Fürst, M Loirat, P Chevallier, J El-Cheikh, T Guillaume, J Delaunay, S Le Gouill, P Moreau, D Blaise and M Mohty Leukemia 2013 27: 2113-2117; advance online publication, June 11, 2013; 10.1038/leu.2013.170 Abstract | Full Text ACUTE LEUKEMIAS SYK regulates mTOR signaling in AML J Carnevale, L Ross, A Puissant, V Banerji, R M Stone, D J DeAngelo, K N Ross and K Stegmaier Leukemia 2013 27: 2118-2128; advance online publication, March 28, 2013; 10.1038/leu.2013.89 Abstract | Full Text Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells S Scotland, E Saland, N Skuli, F de Toni, H Boutzen, E Micklow, I Sénégas, R Peyraud, L Peyriga, F Théodoro, E Dumon, Y Martineau, G Danet-Desnoyers, F Bono, C Rocher, T Levade, S Manenti, C Junot, J-C Portais, N Alet, C Récher, M A Selak, M Carroll and J-E Sarry Leukemia 2013 27: 2129-2138; advance online publication, April 9, 2013; 10.1038/leu.2013.107 Abstract | Full Text F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity A Kruczynski, A Pillon, L Créancier, I Vandenberghe, B Gomes, V Brel, E Fournier, J-P Annereau, E Currie, Y Guminski, D Bonnet, C Bailly and N Guilbaud Leukemia 2013 27: 2139-2148; advance online publication, April 9, 2013; 10.1038/leu.2013.108 Abstract | Full Text Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis C Fernandez, M C Santos-Silva, A López, S Matarraz, M Jara-Acevedo, J Ciudad, M L Gutierrez, M L Sánchez, C Salvador-Osuna, M J Berruezo, J Á Díaz-Arias, A M Palomo-Hernández, E Colado, N González, D Gallardo, A Asensio, R García-Sánchez, R Saldaña, C Cerveró, A Carboné-Bañeres, O Gutierrez and A Orfao Leukemia 2013 27: 2149-2156; advance online publication, April 12, 2013; 10.1038/leu.2013.109 Abstract | Full Text Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML J F Nomdedéu, M Hoyos, M Carricondo, E Bussaglia, C Estivill, J Esteve, M Tormo, R Duarte, O Salamero, M P Q de Llano, A García, J Bargay, I Heras, J M Martí-Tutusaus, A Llorente, J M Ribera, D Gallardo, A Aventin, S Brunet and J Sierra On behalf of the CETLAM Group Leukemia 2013 27: 2157-2164; advance online publication, April 15, 2013; 10.1038/leu.2013.111 Abstract | Full Text The MLL recombinome of acute leukemias in 2013 OPEN C Meyer, J Hofmann, T Burmeister, D Gröger, T S Park, M Emerenciano, M Pombo de Oliveira, A Renneville, P Villarese, E Macintyre, H Cavé, E Clappier, K Mass-Malo, J Zuna, J Trka, E De Braekeleer, M De Braekeleer, S H Oh, G Tsaur, L Fechina, V H J van der Velden, J J M van Dongen, E Delabesse, R Binato, M L M Silva, A Kustanovich, O Aleinikova, M H Harris, T Lund-Aho, V Juvonen, O Heidenreich, J Vormoor, W W L Choi, M Jarosova, A Kolenova, C Bueno, P Menendez, S Wehner, C Eckert, P Talmant, S Tondeur, E Lippert, E Launay, C Henry, P Ballerini, H Lapillone, M B Callanan, J M Cayuela, C Herbaux, G Cazzaniga, P M Kakadiya, S Bohlander, M Ahlmann, J R Choi, P Gameiro, D S Lee, J Krauter, P Cornillet-Lefebvre, G Te Kronnie, B W Schäfer, S Kubetzko, C N Alonso, U zur Stadt, R Sutton, N C Venn, S Izraeli, L Trakhtenbrot, H O Madsen, P Archer, J Hancock, N Cerveira, M R Teixeira, L Lo Nigro, A Möricke, M Stanulla, M Schrappe, L Sedék, T Szczepański, C M Zwaan, E A Coenen, M M van den Heuvel-Eibrink, S Strehl, M Dworzak, R Panzer-Grümayer, T Dingermann, T Klingebiel and R Marschalek Leukemia 2013 27: 2165-2176; advance online publication, April 30, 2013; 10.1038/leu.2013.135 Abstract | Full Text MYELODYSPLASIAS Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells Y Wei, R Chen, S Dimicoli, C Bueso-Ramos, D Neuberg, S Pierce, H Wang, H Yang, Y Jia, H Zheng, Z Fang, M Nguyen, I Ganan-Gomez, B Ebert, R Levine, H Kantarjian and G Garcia-Manero Leukemia 2013 27: 2177-2186; advance online publication, March 29, 2013; 10.1038/leu.2013.91 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression C Marty, C Lacout, N Droin, J-P Le Couédic, V Ribrag, E Solary, W Vainchenker, J-L Villeval and I Plo Leukemia 2013 27: 2187-2195; advance online publication, April 5, 2013; 10.1038/leu.2013.102 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 J C Strefford, L-A Sutton, P Baliakas, A Agathangelidis, J Malčíková, K Plevova, L Scarfó, Z Davis, E Stalika, D Cortese, N Cahill, L B Pedersen, P F di Celle, T Tzenou, C Geisler, P Panagiotidis, A W Langerak, N Chiorazzi, S Pospisilova, D Oscier, F Davi, C Belessi, L Mansouri, P Ghia, K Stamatopoulos and R Rosenquist Leukemia 2013 27: 2196-2199; advance online publication, April 5, 2013; 10.1038/leu.2013.98 Abstract | Full Text Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity OPEN S Hörl, Z Bánki, G Huber, A Ejaz, D Windisch, B Muellauer, E Willenbacher, M Steurer and H Stoiber Leukemia 2013 27: 2200-2208; advance online publication, June 13, 2013; 10.1038/leu.2013.169 Abstract | Full Text NORMAL HEMOPOIESIS p190-B RhoGAP regulates the functional composition of the mesenchymal microenvironment R Raman, R S Kumar, A Hinge, S Kumar, R Nayak, J Xu, K Szczur, J A Cancelas and M-D Filippi Leukemia 2013 27: 2209-2219; advance online publication, April 8, 2013; 10.1038/leu.2013.103 Abstract | Full Text SENSITIVITY AND RESISTANCE TO THERAPY The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells N Garnier, L A Petruccelli, M F Molina, M Kourelis, S Kwan, Z Diaz, H M Schipper, A Gupta, S V del Rincon, K K Mann and W H Miller Jr Leukemia 2013 27: 2220-2228; advance online publication, February 21, 2013; 10.1038/leu.2013.54 Abstract | Full Text ANIMAL MODELS Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway E Alghisi, M Distel, M Malagola, V Anelli, C Santoriello, L Herwig, A Krudewig, C V Henkel, D Russo and M C Mione Leukemia 2013 27: 2229-2241; advance online publication, April 29, 2013; 10.1038/leu.2013.132 Abstract | Full Text Letters to the Editor Top Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, M L Chrétien, B Arnulf, R Szalat, L Garderet, L Benajiba, B Pegourie, C Regny, B Royer, A Caulier, A M Stoppa, S Garciaz, C Touzeau, C Chaleteix, J P Fermand, H A Loiseau, T Facon, M Attal and P Moreau on behalf of Intergroupe Francophone du Myélome (IFM) Leukemia 2013 27: 2242-2244; advance online publication, April 5, 2013; 10.1038/leu.2013.101 Full Text STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia R S Ohgami, L Ma, J D Merker, B Martinez, J L Zehnder and D A Arber Leukemia 2013 27: 2244-2247; advance online publication, April 8, 2013; 10.1038/leu.2013.104 Full Text Highly variable clinical manifestations in a large family with a novel GATA2 mutation P G N J Mutsaers, A A van de Loosdrecht, K Tawana, C Bödör, J Fitzgibbon and F H Menko Leukemia 2013 27: 2247-2248; advance online publication, April 8, 2013; 10.1038/leu.2013.105 Full Text NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model M Mallardo, A Caronno, G Pruneri, P R Raviele, A Viale, P G Pelicci and E Colombo Leukemia 2013 27: 2248-2251; advance online publication, April 15, 2013; 10.1038/leu.2013.114 Full Text Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells S Munir, G H Andersen, A Woetmann, N Ødum, J C Becker and M H Andersen Leukemia 2013 27: 2251-2253; advance online publication, April 18, 2013; 10.1038/leu.2013.118 Full Text Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice M Nieborowska-Skorska, G Hoser, A Hochhaus, T Stoklosa and T Skorski Leukemia 2013 27: 2253-2254; advance online publication, April 22, 2013; 10.1038/leu.2013.123 Full Text Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase G Metzgeroth, J Schwaab, D Gosenca, A Fabarius, C Haferlach, A Hochhaus, N C P Cross, W-K Hofmann and A Reiter Leukemia 2013 27: 2254-2256; advance online publication, April 25, 2013; 10.1038/leu.2013.129 Full Text Long-term follow-up of ETV6–RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor A Enshaei, C J Schwab, Z J Konn, C D Mitchell, S E Kinsey, R Wade, A Vora, C J Harrison and A V Moorman Leukemia 2013 27: 2256-2259; advance online publication, May 2, 2013; 10.1038/leu.2013.136 Full Text Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count G Vaitkeviciene, M Heyman, O G Jonsson, B Lausen, A Harila-Saari, M Stenmarker, M Taskinen, T Zvirblis, A Åsberg, L Groth-Pedersen, L Rageliene and K Schmiegelow Leukemia 2013 27: 2259-2262; advance online publication, May 2, 2013; 10.1038/leu.2013.137 Full Text Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo R Soderquist, D J P Bates, A V Danilov and A Eastman Leukemia 2013 27: 2262-2264; advance online publication, May 3, 2013; 10.1038/leu.2013.138 Full Text Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells X Wu, R C Tschumper and D F Jelinek Leukemia 2013 27: 2264-2267; advance online publication, May 20, 2013; 10.1038/leu.2013.155 Full Text Erratum Top Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity S Hörl, Z Bánki, G Huber, A Ejaz, D Windisch, B Muellauer, E Willenbacher, M Steurer and H Stoiber Leukemia 2013 27: 2268; 10.1038/leu.2013.230 Full Text Advertisement Top cited articles from Blood Cancer Journal  Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms   DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia  Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.